Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

Launched by SUN YAT-SEN UNIVERSITY · Oct 11, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with a specific type of lymphoma called extranodal natural killer/T-cell lymphoma, nasal type (ENKTL). The treatment combines a medication called Sintilimab with a chemotherapy regimen known as P-GemOx, which includes three drugs: pegaspargase, gemcitabine, and oxaliplatin. The goal of the trial is to find out how safe and effective this combination is for patients who have just been diagnosed with advanced stages of this lymphoma.

To participate in the trial, patients need to be between 18 and 75 years old and have a confirmed diagnosis of stage III or IV ENKTL, meaning the cancer is advanced. They should have at least one measurable tumor and have good overall health, with no other serious health issues. Participants can expect regular check-ups and monitoring throughout the treatment to ensure their safety and to assess how well the treatment is working. This trial is currently looking for new participants, so it could be an option for those who qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • biopsy proved extranodal natural killer/T-cell lymphoma, nasal type;
• • newly diagnosed stage III/IV patients;
• • at least one evaluable lesion；
• • ECOG PS 0-2;
• • 18-75 years; without other malignancy;
• • proper functioning of the major organs.
• Exclusion Criteria:
• • hemophagocytic syndrome or aggressive NK cell leukemia;
• • involvement of central nervous system;
• • previously received treatment of chemotherapy, radiotherapy, immunotherapy or biotherapy for lymphoma；